Close Menu

NEW YORK – Guardant Health has initiated its planned ECLIPSE trial (Evaluation of ctDNA Lunar Assay In an Average Patient Screening Encounter), a 10,000-patient observational study that will evaluate the performance of the company's Lunar-2 circulating cell-free DNA test in detecting colorectal cancer in average-risk adults. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.